RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?

Response Evaluation Criteria In Solid Tumors (RECIST) is still the predominant criteria base for assessing tumor burden in oncology clinical trials. Despite several improvements that followed its first publication, RECIST continues to allow readers a lot of freedom in their evaluations. Notably in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannessi, Antoine, Beaumont, Hubert, Liu, Yan, Bertrand, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Educational Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973344/
https://www.ncbi.nlm.nih.gov/pubmed/33738548
http://dx.doi.org/10.1186/s13244-021-00976-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973344/
https://www.ncbi.nlm.nih.gov/pubmed/33738548
http://dx.doi.org/10.1186/s13244-021-00976-w

Ejemplares similares